Diffuse large B cell lymphoma: How can we cure more patients in 2012?

Research output: Contribution to journalReview article

10 Scopus citations

Abstract

Clinically this chapter will focus on 3 important issues critical in the management of diffuse large B cell lymphoma (DLBCL) in 2012: risk stratification, interim PET-CT scanning and the role of high dose therapy and ASCT in the rituximab era for patients with relapsed and primary refractory disease.

Original languageEnglish (US)
Pages (from-to)41-47
Number of pages7
JournalBest Practice and Research: Clinical Haematology
Volume25
Issue number1
DOIs
StatePublished - Mar 1 2012
Externally publishedYes

Keywords

  • FDG-PET
  • cell or origin
  • diffuse large B cell lymphoma
  • double hit lymphoma

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Diffuse large B cell lymphoma: How can we cure more patients in 2012?'. Together they form a unique fingerprint.

  • Cite this